Once again, I find myself debating on whether to dump my Adamis Pharmaceuticals (ADMP) shares or to hold onto them in hopes the company can turn things around. The company reported another disappointing earnings report that revealed a miss on EPS and revenue. Admittedly, the company's poor Q1 performance was primarily due to COVID-19 and the nation’s lockdown measures. However, I was hoping to hear some optimism from the company’s c-suite during their earnings call but the call was lackluster despite a new US commercial agreement for SYMJEPI and ZIMHI. What is more,